Company Overview and News

Mazda sees Malaysia as springboard to Asean

2017-04-10 theedgemarkets
KUALA LUMPUR: Mazda Malaysia Sdn Bhd, a 30%-owned associate of Bermaz Auto Bhd, is eyeing a larger slice of the pie in the Asean markets, as the automotive firm targets to export the locally assembled CX-5 to Cambodia, Indonesia and Myanmar in the second half of this year.

EcoWorld, SapuraKencana, AirAsia, Gamuda, Poh Kong, Mitrajaya, Masteel, Bermaz Auto and MQ Technology

2016-12-08 theedgemarkets
KUALA LUMPUR (Dec 8): Based on corporate announcements and news flow today, companies that may be in focus tomorrow (Dec 9) could include: EcoWorld, SapuraKencana, AirAsia, Gamuda, Poh Kong, Mitrajaya, Masteel, Bermaz Auto and MQ Technology.

Wheels of business still spins for Vincent Tan

He sticks to an important rule – not to fall in love with any of his businesses

KLCI stays flat as Budget 2017 lacks impetus to lift sentiment

2016-10-24 theedgemarkets
KUALA LUMPUR (Oct 24): The FBM KLCI remained flat at mid-morning as measures announced in Budget 2017 were seen as lacking the impetus to lift market sentiment.

Muted response to Budget 2017

2016-10-24 theedgemarkets
KUALA LUMPUR (Oct 24): The FBM KLCI kicked off the week today on a muted note in the aftermath of the tabling of Budget 2017 last Friday.

First Car Buyer Scheme laden with risks, says MIDF Research

2016-10-12 theedgemarkets
KUALA LUMPUR (Oct 12): A planned First Car Buyer Scheme may create a temporary uptick in car sales but could eventually result in a sharp drop in volume and overhang in the market, according to MIDF Research.

Breakfast briefing: Friday, October 7

MarketWrap: Major US stock indexes closed little changed on Thursday, even as declining names outnumbered advancers, ahead of job market data seen as key to determine whether the Federal Reserve will raise rates before the end of the year. - Reuters The DJIA fell 12.53 points, or 0.07%, to 18,268.5, the S&P 500 gained 1.04 points, or 0.05%, to 2,160.77 and the Nasdaq dropped 9.17 points, or 0.17%, to 5,306.

Berjaya’s Q1 pre-tax profit plunges to RM71.61m

2016-09-30 themalaymailonline
KUALA LUMPUR, Sept 30 — Berjaya Corp Bhd’s pre-tax profit plunged to RM71.61 million in the first quarter ended July 31, 2016 from RM183.84 in the same period last year.

KLCI opens lower as select blue chips weigh

2016-09-21 theedgemarkets
KUALA LUMPUR (Sept 21): The FBM KLCI opened lower this morning in line with the cautious regional markets, weighed by losses at select blue chips.

'Overweight' rating stays for construction sector

THE prospect for the construction sector is positive, driven by an anticipated core earnings growth of 15% year-on-year in 2017 due to record high order books for most companies.

Breakfast briefing: Friday, September 9

MarketWrap: US stocks dipped on Thursday, pulled lower by Apple after its latest iPhone failed to impress Wall Street, but gains in energy shares limited the decline. - Reuters The DJIA fell 46.23 points, or 0.25%, to 18,479.91, the S&P 500 lost 4.86 points, or 0.22%, to 2,181.3 and the Nasdaq dropped 24.44 points, or 0.46%, to 5,259.48. Forex summary *The ringgit lost 0.69% to 4.0685 per US$ *It was 0.

KLCI likely to remain lacklustre in tandem with global peers

2016-09-08 theedgemarkets
KUALA LUMPUR (Sept 9): The FBM KLCI is likely to stay lacklustre today in tandem with the lower overnight close at most global markets.

BAuto's Mazda distributing unit in Philippines to be listed

2016-09-08 theedgemarkets
KUALA LUMPUR (Sept 8): Berjaya Auto Bhd (BAuto) said its 60.4%-owned subsidiary in the Philippines intends to seek a listing on the main board of the Philippine Stock Exchange.

BAuto’s Philippine distribution arm eyes listing

BAuto's domestic Mazda sales volume in Q1 was hit by poor consumer sentiment, uncertainties in the local and global economy, and supply constraint on certain completely knocked down models.

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...